<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>102(5)</volume><submitter>Wei X</submitter><pubmed_abstract>Accumulating studies demonstrated that DNA methylation may be potential prognostic hallmarks of various cancers. However, few studies have focused on the power of DNA methylation for prognostic prediction in patients with stage III to IV ovarian cancer (OC). Therefore, constructing a methylomics-related indicator to predict overall survival (OS) of stage III to IV OC was urgently required. A total of 520 OC patients with 485,577 DNA methylation sites from TCGA database were selected to develop a robust DNA methylation signature. The 520 patients were clustered into a training group (70%, n = 364 samples) and an internal validation group (30%, n = 156). The training group was used for digging a prognostic predictor based on univariate Cox proportional hazard analysis, least absolute shrinka</pubmed_abstract><journal>Medicine</journal><pagination>e32766</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9901957</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A methylomics-associated nomogram predicts the overall survival risk of stage III to IV ovarian cancer.</pubmed_title><pmcid>PMC9901957</pmcid><pubmed_authors>Hu W</pubmed_authors><pubmed_authors>Wei X</pubmed_authors><pubmed_authors>Mao K</pubmed_authors></additional><is_claimable>false</is_claimable><name>A methylomics-associated nomogram predicts the overall survival risk of stage III to IV ovarian cancer.</name><description>Accumulating studies demonstrated that DNA methylation may be potential prognostic hallmarks of various cancers. However, few studies have focused on the power of DNA methylation for prognostic prediction in patients with stage III to IV ovarian cancer (OC). Therefore, constructing a methylomics-related indicator to predict overall survival (OS) of stage III to IV OC was urgently required. A total of 520 OC patients with 485,577 DNA methylation sites from TCGA database were selected to develop a robust DNA methylation signature. The 520 patients were clustered into a training group (70%, n = 364 samples) and an internal validation group (30%, n = 156). The training group was used for digging a prognostic predictor based on univariate Cox proportional hazard analysis, least absolute shrinka</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-21T18:08:27.488Z</modification><creation>2025-04-05T17:08:12.752Z</creation></dates><accession>S-EPMC9901957</accession><cross_references><pubmed>36749233</pubmed><doi>10.1097/MD.0000000000032766</doi></cross_references></HashMap>